Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!



MagazineApril 2009 (Vol. 20 Issue 1)Actimmune

Researchers have abandoned trials on the drug Actimmune as a treatment

Researchers have abandoned trials on the drug Actimmune as a treatmentfor idiopathic pulmonary fibrosis (IPF) after patients died while taking partin the study.

IPF is a chronic lung disease, and sufferers often die from severe short-ness of breath. So far, no drug has been developed to treat the condition, and the manufacturers of Actimmune believed that this drug could be the answer. It's a synthetic version of interferon gamma-1b, designed to reduce infections in patients with chronic granulomatous disease, a rare, congenital disorder of the white blood cells.

But when researchers tested Actim-mune on patients with IPF, they found that 14.5 per cent of patients died compared with 12.7 per cent with a placebo ( HCP/interferon_gamma_1bHCP.htm).

Keeping your knees fit for life

Female hair loss

You may also be interested in...

Sign up for free today

Sign up now to get your FREE 17-point Plan to Great Health

Free membership gives you access to our latest news reports, use of our community area, forums, blogs, readers' health tips and our twice-weekly
e-news letter.

WDDTY Recommends

Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, cancer, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2016 WDDTY Publishing Ltd.
All Rights Reserved